492 results match your criteria boston keratoprosthesis


Short-Term Outcomes of Pediatric Keratoprosthesis With the Near-Complete Conjunctival Flap.

Cornea 2021 Jun;40(6):679-684

Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY.

Purpose: The Boston keratoprosthesis (KPro) has been used for certain indications in pediatric patients with congenital corneal opacities. Here, we describe the use of a near-complete conjunctival flap at the time of Boston type 1 KPro surgery in pediatric patients, with the goal of improving pediatric KPro outcomes.

Methods: We performed a retrospective chart review of 21 eyes from 16 patients who received their first KPro before the age of 18 years at a tertiary care center in Rochester, NY. Read More

View Article and Full-Text PDF

Continuous Contact Lens Wear in Boston Type 1 Keratoprosthesis: Why Are We Still Debating?

Authors:
Maria S Cortina

Eye Contact Lens 2021 May;47(5):233-234

Department of Ophthalmology and Visual Sciences, University of Illinois Eye and Ear Infirmary, Chicago, IL.

View Article and Full-Text PDF

Tear Film Cytokine Profile of Patients With the Boston Keratoprosthesis Type 1: Comparing Patients With and Without Glaucoma.

Invest Ophthalmol Vis Sci 2021 Apr;62(4):20

Department of Ophthalmology, Université de Montréal, Centre hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Purpose: Inflammatory cytokines are involved in glaucoma pathogenesis. The purpose is to compare cytokine levels in the tear film of Boston keratoprosthesis (KPro) patients with and without glaucoma, relative to controls, and correlate levels with clinical parameters.

Methods: This cross-sectional study enrolled 58 eyes (58 patients): 41 KPro eyes with glaucoma, 7 KPro eyes without glaucoma, and 10 healthy controls. Read More

View Article and Full-Text PDF

Frozen versus fresh corneal graft carriers in Boston keratoprosthesis surgery: 10-year outcomes.

Can J Ophthalmol 2021 Mar 26. Epub 2021 Mar 26.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montréal, Qué.

Objective: To compare 10-year clinical outcomes of frozen versus fresh corneal graft carriers for the Boston Keratoprosthesis type 1 (KPro).

Design: Prospective, non-masked randomized controlled trial.

Participants: Nineteen eyes of 19 patients having undergone Boston KPro type 1 implantation using a fresh or frozen graft carrier. Read More

View Article and Full-Text PDF

[Treatment of vascularized high-risk eyes with a Boston keratoprosthesis].

Ophthalmologe 2021 Mar 17. Epub 2021 Mar 17.

Zentrum für Augenheilkunde, Medizinische Fakultät, Universitätsklinik Köln, Kerpener Str. 62, 50924, Köln, Deutschland.

Background: In severely compromised and vascularized high-risk eyes, the Boston keratoprosthesis procedure is often the last treatment option. The transparency of the optics is not impaired by endothelial immune reactions.

Methods: This review article discusses relevant literature as well as our own data and experiences with the Boston keratoprosthesis in high-risk eyes. Read More

View Article and Full-Text PDF

Penetrating keratoplasty using collagen crosslinked donor tissue: A case report.

Am J Ophthalmol Case Rep 2021 Jun 24;22:101039. Epub 2021 Feb 24.

Massachusetts Eye and Ear Infirmary Boston, USA.

Purpose: In patients with corneal melt, pretreatment crosslinking (CXL) of donor tissue prior to placement of Boston keratoprosthesis (K-Pro I) decreases graft failure. We report a case of corneal sparing in a phthisical eye following penetrating keratoplasty (PKP) with pretreatment CXL of the donor cornea.

Observations: A 69-year-old female with a history of familial aniridia and bilateral K-Pro I placement. Read More

View Article and Full-Text PDF

Long-term outcomes of Boston keratoprosthesis type I: the Chinese People's Liberation Army General Hospital experience.

Br J Ophthalmol 2021 Mar 5. Epub 2021 Mar 5.

Department of Ophthalmology, General Hospital of People's Liberation Army, Beijing, China

Purpose: To report the long-term outcomes of Boston keratoprosthesis type I (B-KPro type I) implantation in the management of severe ocular surface disorders.

Methods: Retrospective case series. Patients who underwent B-KPro type I implantation at the People's Liberation Army General Hospital were enrolled between March 2011 and September 2019. Read More

View Article and Full-Text PDF

Toward electron-beam sterilization of a pre-assembled Boston keratoprosthesis.

Ocul Surf 2021 Mar 3;20:176-184. Epub 2021 Mar 3.

Disruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, MA, USA. Electronic address:

Purpose: To evaluate the effects of electron-beam (E-beam) irradiation on the human cornea and the potential for E-beam sterilization of Boston keratoprosthesis (BK) devices when pre-assembled with a donor cornea prior to sterilization.

Methods: Human donor corneas and corneas pre-assembled in BK devices were immersed in recombinant human serum albumin (rHSA) media and E-beam irradiated at 25 kGy. Mechanical (tensile strength and modulus, and compression modulus), chemical, optical, structural, and degradation properties of the corneal tissue after irradiation and after 6 months of preservation were evaluated. Read More

View Article and Full-Text PDF

Time to achieve best postoperative visual acuity following Boston keratoprosthesis surgery.

Br J Ophthalmol 2021 Mar 3. Epub 2021 Mar 3.

Ophthalmology, Université de Montréal, Montreal, Quebec, Canada.

Background/aims: To evaluate the time needed for patients with Boston type 1 keratoprosthesis (KPro) to reach their best-corrected visual acuity (BCVA) and all contributing factors.

Methods: We retrospectively reviewed 137 consecutive eyes from 118 patients, measured how long they needed to reach their BCVA and looked at factors that might affect this time duration including patient demographics, ocular comorbidities and postoperative complications.

Results: The mean follow-up was 5. Read More

View Article and Full-Text PDF

Infectious Keratitis After Boston Type 1 Keratoprosthesis Implantation.

Cornea 2021 Feb 24. Epub 2021 Feb 24.

Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, CA; Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran; Ophthalmology Department, Paris University, Cochin Hospital, Paris, France; and Department of Ophthalmology, Centre hospitalier de l'Université de Montréal, Montréal, Québec, Canada.

Purpose: To identify the incidence, risk factors, and outcomes of infectious keratitis after Boston type 1 keratoprosthesis (kpro) implantation.

Methods: Retrospective case series of kpro procedures at the Stein Eye Institute and the Centre Hospitalier de l'Université de Montréal between May 1, 2004, and December 31, 2018. Data were collected regarding ocular history, operative details, postoperative management, microbiologic profile, treatment, and outcomes. Read More

View Article and Full-Text PDF
February 2021

Electron Beam Sterilization of Poly(Methyl Methacrylate)-Physicochemical and Biological Aspects.

Macromol Biosci 2021 Apr 24;21(4):e2000379. Epub 2021 Feb 24.

Disruptive Technology Laboratory, Massachusetts Eye and Ear and Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, MA, 02114, USA.

Electron beam (E-beam) irradiation is an attractive and efficient method for sterilizing clinically implantable medical devices made of natural and/or synthetic materials such as poly(methyl methacrylate) (PMMA). As ionizing irradiation can affect the physicochemical properties of PMMA, understanding the consequences of E-beam sterilization on the intrinsic properties of PMMA is vital for clinical implementation. A detailed assessment of the chemical, optical, mechanical, morphological, and biological properties of medical-grade PMMA after E-beam sterilization at 25 and 50 kiloGray (kGy) is reported. Read More

View Article and Full-Text PDF

Long-term outcomes following primary versus secondary Boston keratoprosthesis type 1 implantation.

Br J Ophthalmol 2021 Feb 23. Epub 2021 Feb 23.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

Background/aims: To compare long-term outcomes of primary versus secondary (postgraft failure) Boston keratoprosthesis type 1 (KPro) implantation.

Methods: Medical records of patients at the Centre hospitalier de l'Université de Montréal having undergone KPro implantation between 2008 and 2017 were reviewed and included if they had a preoperative Snellen best-corrected visual acuity (BCVA) of 20/100 or worse and a minimum of 5 years of follow-up. Eighty-two eyes were separated into two cohorts (40 primary, 42 secondary KPro) and BCVA, complications and device retention were evaluated between groups. Read More

View Article and Full-Text PDF
February 2021

Glaucoma Risk Factors and Outcomes Following Boston Keratoprosthesis Type 1 Surgery.

Am J Ophthalmol 2021 Jan 22;226:56-67. Epub 2021 Jan 22.

Department of Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada. Electronic address:

Purpose: To evaluate glaucoma risk factors and associated outcomes of the Boston keratoprosthesis type I (KPro).

Design: Clinical case-control study.

Methods: This is a single-center study of 140 eyes of 118 patients who underwent KPro surgery between October 2008 and March 2017 by a single surgeon. Read More

View Article and Full-Text PDF
January 2021

Sputter Deposition of Titanium on Poly(Methyl Methacrylate) Enhances Corneal Biocompatibility.

Transl Vis Sci Technol 2020 12 23;9(13):41. Epub 2020 Dec 23.

Disruptive Technology Laboratory and Schepens Eye Research Institute, Massachusetts Eye and Ear; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

Purpose: To evaluate titanium (Ti) sputtering of the poly(methyl methacrylate) (PMMA) stem of the Boston Keratoprosthesis (BK) as a method to enhance interfacial adhesion between the PMMA and the recipient corneal tissue.

Methods: PMMA specimens were plasma treated with Ar/O and coated with Ti using a DC magnetron sputtering instrument. The topography and hydrophilicity of the surfaces were characterized using atomic force microscopy and a water contact angle instrument, respectively. Read More

View Article and Full-Text PDF
December 2020

TNF-α Inhibitors for the Management of Intractable Corneal Melt: Report of Three Cases and Review of the Literature.

Eye Contact Lens 2021 Jan 4;Publish Ahead of Print. Epub 2021 Jan 4.

Department of Ophthalmology (C.A.U., D.Ö., B.A., I.D.), Dokuz Eylul University, Izmir, Turkey; Izmir Biomedicine and Genome Center (C.A.U.), Izmir, Turkey; and Department of Rheumatology (M.B., A.K.), Dokuz Eylul University, Izmir, Turkey.

Objective: To report three consecutive cases with noninfectious corneal melting, whose disease progression could only be halted with tumor necrosis-α (TNF-α) inhibitor infusion, with a review of the relevant literature.

Materials And Methods: Patients with toxic epidermal necrolysis, severe alkaline burn, and Sjögren syndrome had experienced severe corneal melting following penetrating keratoplasty, Boston type 1 keratoprosthesis implantation or spontaneously, respectively. Topical autologous serum eye-drops, medroxyprogesterone, and acetylcysteine formulations; frequent nonpreserved lubrication; systemic tetracyclines and vitamin-C supplements; topical and systemic steroids and steroid-sparing agents; surgical approaches including amniotic membrane transplantation, tectonic graft surgery; and tarsorraphy failed to alter the disease courses. Read More

View Article and Full-Text PDF
January 2021

Letter to the Editor: Visual Field Characteristics of Type I Boston Keratoprosthesis Patients Without Glaucoma.

J Glaucoma 2021 Mar;30(3):e124-e125

Department of Ophthalmology, Université de Montréal, Centre Hospitalier de l'Université de Montréal (CHUM) Montreal, QC, Canada.

View Article and Full-Text PDF

Endophthalmitis in Eyes With the Boston Type I Keratoprosthesis: Incidence, Recurrence, Risk Factors, and Outcomes.

Cornea 2020 Dec 31;Publish Ahead of Print. Epub 2020 Dec 31.

Department of Ophthalmology, Centre hospitalier de l'Université de Montréal, Montreal, Canada; and Department of Ophthalmology, King Abdulaziz University, Jeddah, Saudi Arabia.

Purpose: To determine the incidence and recurrence of Boston type I keratoprosthesis (KPro)-associated endophthalmitis, and its microbiological profile, risk factors, and outcomes.

Methods: This is a retrospective study of 158 consecutive KPro procedures with a median follow-up of 78.4 months. Read More

View Article and Full-Text PDF
December 2020

Short-Term Interim Results of Clinical Outcomes and Complications After Implantation of Boston Keratoprosthesis in Japanese Patients.

Cornea 2021 Mar;40(3):e6-e7

Département d'ophtalmologie, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

View Article and Full-Text PDF

Ochrobactrum anthropi Keratitis in a Boston Type 1 Keratoprosthesis Recipient.

Cornea 2021 May;40(5):662-663

Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA.

Purpose: To report a case of Ochrobactrum anthropi keratitis in an eye with a Boston type 1 keratoprosthesis.

Methods: This is a case report and review of the literature.

Results: A 78-year-old man with a history of implantation of a Boston type 1 keratoprosthesis in the left eye presented for a routine follow-up with no acute complaints. Read More

View Article and Full-Text PDF

Modified Boston Type-II Keratoprosthesis Implantation with Autologous Auricular Cartilage Reinforcement.

Ocul Surf 2020 Nov 25. Epub 2020 Nov 25.

Department of Ophthalmology, Chinese PLA General Hospital, Beijing 100853, China. Electronic address:

View Article and Full-Text PDF
November 2020

Intrinsic Optical Properties of Boston Keratoprosthesis.

Transl Vis Sci Technol 2020 11 3;9(12):10. Epub 2020 Nov 3.

Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.

Purpose: To benchmark the optical performance of Boston Keratoprosthesis (B-KPro).

Methods: Back focal lengths (BFL) of B-KPros for various eye axial lengths were measured using an optical bench, International Organization for Standardization-certified for intraocular lens characterization, and compared against manufacturer's specification. The modulation transfer function (MTF) and the resolution efficiencies were measured. Read More

View Article and Full-Text PDF
November 2020

Automated Keratopigmentation in Boston Type 1 Keratoprosthesis: An Aesthetic Alternative.

Cornea 2020 Dec;39(12):1578-1580

Research Department, Oftalmosalud Institute of Eyes, Lima, Peru.

Two male patients, aged 64 and 55 years old, presented at the cornea department for a Boston type 1 keratoprosthesis (Kpro I) implantation after multiple corneal graft failures. After surgery, they achieved a best corrected visual acuity of 20/200 and 20/150, respectively. However, they manifested photophobia and aesthetic complaints. Read More

View Article and Full-Text PDF
December 2020

Visual Field Characteristics of Type I Boston Keratoprosthesis Patients without Glaucoma.

J Glaucoma 2020 Nov 3;Publish Ahead of Print. Epub 2020 Nov 3.

Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, UNIFESP, São Paulo, Brazil.

Purpose: To determine visual field findings in Boston Type 1-Kpro (BI-Kpro) patients without glaucoma. Characterize normal threshold values and global indices using standard automated perimetry and characterize visual field amplitude using Goldmann's manual perimetry.

Methods: This cross-sectional prospective non-interventional study included patients (n=6 patients, 6 eyes) with BI-KPro who had normal optical coherence tomography and fundoscopic evaluation of the optic disc and retina. Read More

View Article and Full-Text PDF
November 2020

B-scan ultrasound, visual electrophysiology and perioperative videoendoscopy for predicting functional results in keratoprosthesis candidates.

Br J Ophthalmol 2020 Oct 22. Epub 2020 Oct 22.

Department of Ophthalmology and Visual Sciences, Federal University of São Paulo, São Paulo, Brazil

Background/aims: We analysed the ability of B-scan ultrasound, ocular electrophysiology testing and videoendoscopic examination for predicting visual prognosis in Boston Type 1 keratoprosthesis (KPro-1) candidates. Indirect anatomical and electrophysiological findings and results from direct endoscopic evaluations were correlated with postoperative functional data.

Methods: In this prospective and interventional study, we included 13 individuals who had previously been indicated for Kpro-1 surgery. Read More

View Article and Full-Text PDF
October 2020

Mid-term prognosis of type I Boston keratoprosthesis reimplantation.

Br J Ophthalmol 2020 Oct 14. Epub 2020 Oct 14.

Ophthalmology, Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, H2X 3E4, Canara

Aim: To examine the mid-term visual and anatomical prognosis of patients who require reimplantation of a second Boston keratoprosthesis type 1 (B-KPro).

Methods: Retrospective observational case series of 122 patients (141 eyes) who received a B-KPro at a single institution were reviewed. Eyes that underwent a second B-KPro were included in the study. Read More

View Article and Full-Text PDF
October 2020

Idiopathic Vitritis after Boston Type 1 Keratoprosthesis Implantation: Incidence, Risk Factors and Outcomes in a Multicentric Cohort.

Ocul Immunol Inflamm 2020 Oct 15:1-7. Epub 2020 Oct 15.

Stein Eye Institute, David Geffen School of Medicine, University of California , Los Angeles, Los Angeles, California, USA.

Purpose: To determine incidence, risks factors for, and outcomes of idiopathic vitritis (IV) after Boston type 1 keratoprosthesis (KPro) implantation.

Methods: Retrospective, consecutive case series. Risk factors were analyzed between IV group and No IV group. Read More

View Article and Full-Text PDF
October 2020

Outcomes and complications of Boston keratoprosthesis type I implantation in unilateral versus bilateral corneal blindness.

Can J Ophthalmol 2021 Apr 28;56(2):130-136. Epub 2020 Sep 28.

Department of Ophthalmology, Centre Hospitalier de l'Université de Montréal, Montreal, Que.

Objective: To compare the outcomes of Boston keratoprosthesis (KPro) type I implantation between patients who are legally blind versus sighted in the contralateral eye.

Design: Single centre retrospective comparative case series.

Participants: Patients who underwent Boston KPro type I implantation between 2008 and 2017. Read More

View Article and Full-Text PDF

Short-term Interim Results of Clinical Outcomes and Complications After Implantation of Boston Keratoprosthesis in Japanese Patients.

Cornea 2020 Nov;39 Suppl 1:S28-S33

Department of Ophthalmology, Miyata Eye Hospital, Miyazaki, Japan.

Keratoprosthesis is used for corneal transplantation in high-risk patients who require penetrating keratoplasty (PKP). Boston keratoprosthesis (BKpro) is a representative type of keratoprosthesis used worldwide. In Japan, the first BKpro was implanted in an eye after multiple corneal graft failures in 2008, but its use remains limited. Read More

View Article and Full-Text PDF
November 2020